Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders

Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.

Emergent BioSolutions
some improvising was going on in overcrowded plant • Source: Alamy

US Food and Drug Administration investigators painted a portrait 20 April of an Emergent BioSolutions, Inc. facility so overwhelmed by the challenge of manufacturing drug substances for two COVID-19 vaccines that it could not prevent their cross-contamination.

The facilities were not properly sized, configured or cleaned, workers were not following procedures, and risks abounded for microbiological contamination...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet